Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices 76837 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NCAB: 

https://deainfo.nci.nih.gov/advisory/ncab/ 

ncabmeetings.htm, where an agenda, 

instructions for accessing the virtual NCAB 

meetings, and any additional information for 

the meetings will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: November 2, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–24578 Filed 11–6–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Frederick National 

Laboratory Advisory Committee to the 

National Cancer Institute. 

The meeting will be held virtually 

and is open to the public. Individuals 

who plan to view the virtual meeting 

and need special assistance or other 

reasonable accommodations to view the 

meeting, should notify the Contact 

Person listed below in advance of the 

meeting. The meeting will be videocast 

and can be accessed from the NIH 

Videocasting and Podcasting website 

(http://videocast.nih.gov). 

Name of Committee: Frederick National 

Laboratory Advisory Committee to the 

National Cancer Institute. 

Date: February 29, 2024. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: Ongoing and new activities at the 

Frederick National Laboratory for Cancer 

Research. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Christopher D. Kane, 

Ph.D., Health Science Administrator and 

Program Officer, Office of Scientific 

Operations, NCI at Frederick, National 

Cancer Institute, National Institutes of 

Health, 1050 Boyles Street, Building 427, 

Room 4, Frederick, Maryland 21702, 

christopher.kane@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: FNLAC: 

https://deainfo.nci.nih.gov/advisory/fac/ 

fac.htm, where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: November 2, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–24584 Filed 11–6–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Tung at 240–669–5483 or 

peter.tung@nih.gov. Licensing 

information and copies of the patent 

applications listed below may be 

obtained by communicating with the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD, 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Beta Globin Mimetic Peptides and 

Their Use 

Description of Technology: Feedback 

vasodilation by endothelium-derived 

nitric oxide (NO) is under the regulation 

of globins. Inventors discovered that not 

only the alpha globin but also the beta 

globin subunits of hemoglobin are 

expressed in the human artery wall, 

with beta globin interacting directly 

with endothelium-derived nitric oxide 

synthase (eNOS). This discovery of 

tetrameric hemoglobin binding to eNOS 

has led inventors to develop novel 

mimetic peptides that disrupt the 

binding of beta globin to eNOS, 

diminishing the ability of hemoglobin to 

restrict NO release and thereby 

enhancing NO-mediated feedback 

vasodilation. These agents can be used 

to increase NO signaling from 

endothelial cells and thus inhibit, 

prevent, or reverse vasoconstriction. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Novel peptides to treat vascular 

diseases characterized by 

vasoconstriction, excess alpha 

adrenergic signaling, or insufficient 

nitric oxide signaling. Applications 

could range from cerebral vasospasm to 

pulmonary hypertension, to chronic 

kidney disease, to transfusion medicine, 

to erectile dysfunction, and to exercise 

physiology. 

Competitive Advantages: 

• New pathway for regulation of 

vasoconstriction/vasodilation that is 

separate from the pathways that current 

products available for treating nitric 

oxide deficiency target. Combination 

therapy with current vasoconstriction/ 

vasodilation medications of different 

mechanisms may be possible. 

• Enhancement of NO release at the 

junction between the endothelial cell 

and smooth muscle cell may provide 

greater potency and fewer off-target 

effects than other forms of NO delivery. 

Development Stage: 

• Peptides have been tested in human 

and canine arteries ex vivo. 


khammond on DSKJM1Z7X2PROD with NOTICES
76838 Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices 

Inventors: Drs. Hans Ackerman 

(NIAID), Steven Brooks (NIAID), Phillip 

Cruz (NIAID), Rolf Swenson (NHLBI). 

Publications: Brooks, SD et al. 

‘‘Hemoglobin Interacts with Endothelial 

Nitric Oxide Synthase to Regulate 

Vasodilation in Human Resistance 

Arteries’’ https://doi.org/10.1101/ 

2021.04.06.21255004 (This article is a 

preprint and has not been certified by 

peer review). 

Intellectual Property: HHS Reference 

No. E–060–2022–0–US–01; U.S. 

Provisional Application No. 63/328,615, 

filed on April 7, 2022; HHS Reference 

No. E–060–2022–0–PCT–02; PCT 

Application No. PCT/US2023/065432, 

filed on April 6, 2023. 

Licensing Contact: To license this 

technology, please contact Peter Tung at 

240–669–5483 or peter.tung@nih.gov, 

and reference E–060–2022. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the invention. For 

collaboration opportunities, please 

contact Peter Tung at 240–669–5483, or 

peter.tung@nih.gov. 

Dated: November 1, 2023. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2023–24550 Filed 11–6–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–7070–N–80] 

30-Day Notice of Proposed Information 

Collection: Youth Homeless Systems 

Improvement (YHSI) Program; OMB 

Control No.: 2506–0219 

AGENCY: Office of Policy Development 

and Research, Chief Data Officer, HUD. 

ACTION: Notice. 

SUMMARY: HUD is seeking approval from 

the Office of Management and Budget 

(OMB) for the information collection 

described below. In accordance with the 

Paperwork Reduction Act, HUD is 

requesting comment from all interested 

parties on the proposed collection of 

information. The purpose of this notice 

is to allow for an additional 30 days of 

public comment. 

DATES: Comments Due Date: December 

7, 2023. 

ADDRESSES: Interested persons are 

invited to submit comments regarding 

this proposal. Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Interested persons are 

also invited to submit comments 

regarding this proposal and comments 

should refer to the proposal by name 

and/or OMB Control Number and 

should be sent to: Colette Pollard, 

Clearance Officer, REE, Department of 

Housing and Urban Development, 451 

7th Street SW, Room 8210, Washington, 

DC 20410–5000; email 

PaperworkReductionActOffice@

hud.gov. 

FOR FURTHER INFORMATION CONTACT: 

Colette Pollard, Reports Management 

Officer, REE, Department of Housing 

and Urban Development, 451 7th Street 

SW, Washington, DC 20410; email 

Colette.Pollard@hud.gov; telephone 

number (202) 402–3400. This is not a 

toll-free number. HUD welcomes and is 

prepared to receive calls from 

individuals who are deaf or hard of 

hearing, as well as individuals with 

speech or communication disabilities. 

To learn more about how to make an 

accessible telephone call, please visit 

https://www.fcc.gov/consumers/guides/ 

telecommunications-relay-service-trs. 

Copies of available documents 

submitted to OMB may be obtained 

from Ms. Pollard. 

SUPPLEMENTARY INFORMATION: This 

notice informs the public that HUD is 

seeking approval from OMB for the 

information collection described in 

Section A. 

The Federal Register notice that 

solicited public comment on the 

information collection for a period of 60 

days was published on March 20, 2023 

at 88 FR 16648. 

Overview of Information Collection 

Title of Information Collection: Youth 

Homeless Systems Improvement (YHSI). 

OMB Approval Number: 2506–0219. 

Type of Request: Revision. 

Form Number: HUD 2880, SF–LLL, 

SF–424, SF–424B, HUD–424–CBW 

Description of the need for the 

information and proposed use: Congress 

appropriated funds to the Department of 

Housing and Urban Development in 

FY2022 and in FY2023 to competitively 

award funds to selected communities to 

develop projects that implement 

systems infrastructure to better address 

youth homelessness. The YHSI projects 

will focus on systems change to create 

and build capacity for Youth Action 

Boards; collect and use data from 

different systems to improve the youth 

homeless response system; develop 

strong leaders within a community; and 

improve the coordination, 

communication, operation, and 

administration of homeless assistance 

projects, including prevention and 

diversion strategies. This information 

collection revision is to competitively 

award YHSI funds to communities and 

monitor the progress of the funded 

project. This revision is to include two 

additional forms in the approved PRA 

for this program—the HUD–2880, 

Applicant/Recipient Disclosure/Update 

Report, and the 424–CBW Grant 

Application Detailed Budget Worksheet. 

Respondents: Not-for-profit 

institutions; State, Local or Tribal 

Governments. 

Estimated Number of Respondents: 

150. 

Estimated Number of Responses: 190. 

Frequency of Response: Biannual. 

Average Hours per Response: 27. 

Total Estimated Burdens: 2,670. 

Submission documents Number of 

respondents 

Responses 

frequency 

(average) 

Total annual 

responses 

Burden hours 

per response Total hours Hourly rate 

Burden cost 

per 

Information Collection instrument 

Component 1. Project Selection: 

YHSI Project Selection Narratives ................ 100 1 100 22 2,200 $53.67 $118,074.00 

SF–424—Application for Federal Assistance 100 1 100 0 0 53.67 0.00 

SF–424B Assurances for Non-Construction 

Programs ................................................... 100 1 100 0 0 53.67 0.00 

HUD–2880, Applicant/Recipient Disclosure/ 

Update Report ........................................... 100 1 100 0 0 53.67 0.00 

HUD–424–CBW, Grant Application Detailed 

Budget Worksheet ..................................... 100 1 100 0 0 53.67 0.00 

OMB–SF–LLL—Disclosure of Lobbying Activities (where applicable) .......................... 100 1 100 0 0 53.67 0.00 


khammond on DSKJM1Z7X2PROD with NOTICES